Medical/Pharmaceuticals

NIPRO CORPORATION Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States

New medium-cutoff Dialyzer with a Super High-flux membrane brings NIPRO's approach to expanded hemodialysis to United States healthcare providers.  OSAKA, Japan, July 30, 2026 /PRNewswire/ -- NIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food ...

2026-07-30 20:10 2167

NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC

CHENGDU, China, July 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan...

2026-07-30 17:19 2099

Medidata Launches Medidata Plus, an AI-Native Foundation Built to Scale Clinical Portfolios

Built on an award-winning AI foundation, Medidata Plus removes traditional barriers, empowering sponsors and CROs to scale intelligence across entire portfolios SINGAPORE, July 30, 2026 /PRNewswire/ -- Medidata , a Dassault Systèmes brand and leading provider of clinic...

2026-07-30 10:04 3471

Piramal Pharma Limited Announces Results for Q1 FY27

MUMBAI, India, July 29, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the First Quarter (Q1) ended 30th June 2026.   Consolidated Financial Hig...

2026-07-30 03:38 2281

Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms

Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies. NANTONG, China, July 29, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinica...

2026-07-29 21:57 2792

Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma

* FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico's first FTD, recognizing the clinical potential in advanced m...

2026-07-29 20:30 2689

Fosun International Issues Positive Profit Alert: Profit Attributable to Owners of the Parent for 1H2026 Expected to be Approx. RMB 1.5 Billion to RMB1.8 Billion

HONG KONG, July 29, 2026 /PRNewswire/ -- On 29th July, Fosun International (00656.HK) issued a positive profit alert. Its profit attributable to owners of the parent for the first half of 2026 is expected to range from approximately RMB1.5 billion to RMB1.8 billion representing an increase of app...

2026-07-29 17:35 3886

AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer

* ELAHERE is the first and only antibody-drug conjugate (ADC) therapy approved specifically for patients with folate receptor alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, who have received one to three prior s...

2026-07-29 10:00 2506

Australian medtech Navi raises $A6.8 million to commercialise breakthrough paediatric technology in the US

MELBOURNE, Australia and BOSTON, July 29, 2026 /PRNewswire/ -- Melbourne- and Boston-based medical device company Navi Medical Technologies has closed a $A6.8 million capital raise to commercialise its breakthrough paediatric vascular access technology in the United States.

2026-07-29 08:00 2166

Torrey Pines Medicine Secures Angel Round to Advance Next-Generation Ultra-Long-Acting Peptide Therapeutics

Led by Lotus Lake Capital, the financing will accelerate the development of TPM004, a differentiated ultra-long-acting amylin/calcitonin receptor dual agonist, and advance the company's proprietary PepTetris™ peptide discovery platform for obesity, diabetes, and other metabolic diseases * Deve...

2026-07-28 20:00 1714

IHH Healthcare Expands 'IHH Catalyst' to North Asia to Accelerate Clinical Adoption of Healthcare Innovation

Building on the success of its inaugural programme in India, IHH Healthcare is launching IHH Catalyst | North Asia Edition to help startups in Hong Kong, Chinese Mainland and neighbouring markets turn healthcare innovation into real-world clinical impact. HONG KONG and SINGAPORE and KUALA L...

2026-07-28 18:44 1586

New report identifies opportunities to help more patients in Asia Pacific benefit from advances in AFib care

Growing physician confidence in pulsed field ablation highlights the need to strengthen referral pathways, education and healthcare system readiness SINGAPORE, July 28, 2026 /PRNewswire/ -- Boston Scientific today revealed findings from a new report showing that, while physicians in Asia Pacific ...

2026-07-28 11:00 3412

Everest Medicines Announces Participation in Upcoming Investor Conferences

SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Fi...

2026-07-27 23:17 2362

TriNetX Appoints August Calhoun Chief Executive Officer

Jeff Margolis Resumes Chairman Role as Company Completes CEO Transition CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- TriNetX, The Global Truth Engine for Better Human Health™ and operator of the world's leading federated health data network, today announced the appointment ofAugust Calhoun as ...

2026-07-27 23:00 2080

HoneyNaps Registers as Contract Research Organization (CRO), Accelerating AI-Powered Clinical Trial Analytics

* Strengthens specialized AI-powered sleep data analysis services for global pharmaceutical, medical device, and healthcare companies * Targets the rapidly growing global sleep clinical research market with advanced biomarker analytics and continual learning technology * Leverages experience...

2026-07-27 21:52 1149

AsymBio Kicks Off Construction of Fengxian R&D Building to Establish a Full-Lifecycle, One-Stop Biologics Service Ecosystem

SHANGHAI, July 27, 2026 /PRNewswire/ -- AsymBio , a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group  (stock codes: 002821.SZ / 6821.HK), today announced that construction of its ne...

2026-07-27 21:00 2736

Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study (GMCS)

* STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive cases * Findings support the potential value of a comprehensive testing approach that provides both HPV and STI pathogen information * Seegene to v...

2026-07-27 21:00 6404

Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships

TAIPEI, July 27, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics,today reaffirmed its strategic focus on pursuing global li...

2026-07-27 20:20 2283

Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer

* Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. * Offers 5x greater sensitivity vs. in-class instruments with lower detection limits in smaller sample volum...

2026-07-27 20:10 2674

Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors

Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors CAMBRIDGE, Mass...

2026-07-27 20:00 3349
1 ... 9101112131415 ... 644